In this regard, Vellano et al. [13] observed that the treatment of melanoma with BRAF/MEK inhibitor improved recurrence-free survival more efficiently in female than in male patients and, using preclinical models, attributed this significant difference to AR inactivity. This evidence concerns the gene BRAF and melanoma.